HOME > BUSINESS
BUSINESS
- Kaketsuken Submits 1st Japan-Made Hemophilia Inhibitor Treatment for Approval
October 9, 2013
- Takeda’s Norovirus Vaccine Misses Primary Endpoint in PI/II, but Reduces Vomiting, Diarrhea
October 9, 2013
- Chugai Files NDA for ALK Inhibitor Alectinib in Japan for NSCLC
October 9, 2013
- Onychomycosis Treatment Efinaconazole Licensed from Kaken Approved in Canada
October 9, 2013
- Astellas, US Biotech Venture to Collaborate on Mitochondrial Disease Therapies
October 8, 2013
- Quintiles Aims to Expand Business in Japan with More Employees: CEO
October 8, 2013
- Ethical Drug Sales Up 0.7% in August: Crecon Report
October 8, 2013
- 3 Combination Drugs for Asthma, COPD Get Approval to Fuel Competition; NHI Price Listing Expected in November
October 7, 2013
- Novartis AG Pharma Division Head Supports Ministry Panel’s Diovan Investigation Interim Report, Refuses to Comment on Whether Ads Were Exaggerated
October 7, 2013
- Nippon Shinyaku, Pfizer Japan Sign Deal for Promotional Activities for Tramal
October 7, 2013
- Novartis Japan Execs Face 30% Pay Cut amid Diovan Scandal, Compliance Advisory Board to Be Set Up
October 4, 2013
- Mundipharma Initiates Clinical Study of PTCL Treatment Pralatrexate in Japan
October 4, 2013
- Takeda, Tri-I TDI Conclude Research Deal
October 4, 2013
- Number of MRs Down Slightly to 63,846 as of March 2013; Are We Entering an Age of Decline for MRs?
October 4, 2013
- Nichi-Iko, South Korean Biotech Firm Partner Up on Biosimilar Business
October 3, 2013
- Nihon Chouzai to Increase Its Generic Portfolio to 1,000 in 2 Years: President Mitsuhara
October 3, 2013
- Asahi Kasei Pharma, Vernalis Sign Joint Research Agreement for New Drug Discoveries for Autoimmune Diseases
October 3, 2013
- Kissei, JCR to Jointly Develop Nesp Biosimilar
October 2, 2013
- Another Administrative Action Taken Against MTPC on Medway Injection; 3rd in 4 Years
October 2, 2013
- US FDA Approves Brintellix for Treatment of MDD in Adults: Takeda, Lundbeck
October 2, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…